Atopic Dermatitis

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release.

Tape strips that capture the molecular fingerprint of chronic hand eczema indicated broadly shared immune and barrier dysregulations among patients who have and who do not have atopic dermatitis, according to a study abstract.

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.

Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.

Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.

With dozens of topical therapies and systemic treatments available for atopic dermatitis, clinicians have many options. But a pair of reviews in The Journal of Allergy and Clinical Immunology may help them narrow down their choices.

Dermavant Sciences has announced new “highly favorable” phase 3 pruritus data for Vtama cream for the treatment of moderate to severe atopic dermatitis in adults and children aged as young as 2 years, according to a press release.

Colloidal oatmeal 1%, a natural and affordable cream, is just as effective as prescription barrier cream in the treatment of mild to moderate atopic dermatitis in Black children, according to a study.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

Roflumilast cream 0.05% achieved positive results in a pediatric trial of a phase 3 program treating children aged 2 to 5 years with mild to moderate atopic dermatitis, according to an Arcutis Biotherapeutics press release.